News

STAT3d
A cautious culture cost Novo Nordisk its lead in the obesity drug race, former employees say
Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...
Wegovy discount: Price for weight-loss drug gets cut to $199, but there's a catch
Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
FDA crackdown on off-brand Ozempic products set to take effect, threatening supply and access for many
The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...
Pharmaceutical Technology on MSN20d
Novo Nordisk’s CEO to step down as weight loss market share plummets
Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of leadership was required amid fierce glucagon-like peptide 1 receptor agonists ...
Novo Nordisk CEO Lars Jorgensen, who led company into weight loss drugs, to step down
Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...
Fierce Pharma4d
Novo Nordisk signs on to support ADA’s obesity advocacy division
Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...